Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036959 · ClinicalTrials.gov registry record · Phase 1

ABT-751 in Treating Young Patients With Refractory Solid Tumors

A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
Phase 1
Development phase
90
Enrollment target

NCT00036959: Completed Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).

NCT00036959 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036959, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
Phase 1
Development phase
90 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.

Interventions

  • DRUG ABT-751

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2002-03
Est. Completion 2010-02
Phase Phase 1

What the finished NCT00036959 record still lists

NCT00036959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).

The record links to 0 conditions, and to 1 intervention - of which ABT-751 is the first listed.

NCT00036959 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00036959 about?

NCT00036959 is a clinical study titled "ABT-751 in Treating Young Patients With Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.

What is the current status of trial NCT00036959?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2002-03. Estimated completion is 2010-02.

What interventions are being tested in trial NCT00036959?

The interventions under investigation include: ABT-751 (DRUG).

Who is sponsoring clinical trial NCT00036959?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00036959's enrollment target sits among peer trials

90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00036959, the US trial registry maintained by the National Library of Medicine. NCT00036959 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.